RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bonus Biogroup Stock

Bonus Biogroup P/S 2024

Bonus Biogroup P/S

0

Ticker

BONS.TA

ISIN

IL0004850116

WKN

A0Q9T6

As of Sep 27, 2024, Bonus Biogroup's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Bonus Biogroup P/S history

Bonus Biogroup Aktienanalyse

What does Bonus Biogroup do?

The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Bonus Biogroup's P/S Ratio

Bonus Biogroup's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Bonus Biogroup's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Bonus Biogroup's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Bonus Biogroup’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Bonus Biogroup stock

What is the price-to-earnings ratio of Bonus Biogroup?

The price-earnings ratio of Bonus Biogroup is currently 0.

How has the price-earnings ratio of Bonus Biogroup changed compared to last year?

The price-to-earnings ratio of Bonus Biogroup has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Bonus Biogroup high compared to other companies?

Yes, the price-to-earnings ratio of Bonus Biogroup is high compared to other companies.

How does an increase in the price-earnings ratio of Bonus Biogroup affect the company?

An increase in the price-earnings ratio of Bonus Biogroup would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Bonus Biogroup affect the company?

A decrease in the price-earnings ratio of Bonus Biogroup would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Bonus Biogroup?

Some factors that influence the price-earnings ratio of Bonus Biogroup are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Bonus Biogroup pay?

Over the past 12 months, Bonus Biogroup paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bonus Biogroup is expected to pay a dividend of 0 ILS.

What is the dividend yield of Bonus Biogroup?

The current dividend yield of Bonus Biogroup is .

When does Bonus Biogroup pay dividends?

Bonus Biogroup pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bonus Biogroup?

Bonus Biogroup paid dividends every year for the past 0 years.

What is the dividend of Bonus Biogroup?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bonus Biogroup located?

Bonus Biogroup is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bonus Biogroup kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bonus Biogroup from 9/27/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Bonus Biogroup pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Bonus Biogroup in the year 2023?

In the year 2023, Bonus Biogroup distributed 0 ILS as dividends.

In which currency does Bonus Biogroup pay out the dividend?

The dividends of Bonus Biogroup are distributed in ILS.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bonus Biogroup

Our stock analysis for Bonus Biogroup Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bonus Biogroup Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.